BRPI0411316A - uso de uma toxina clostrìdica para reduzir o apetite - Google Patents

uso de uma toxina clostrìdica para reduzir o apetite

Info

Publication number
BRPI0411316A
BRPI0411316A BRPI0411316-0A BRPI0411316A BRPI0411316A BR PI0411316 A BRPI0411316 A BR PI0411316A BR PI0411316 A BRPI0411316 A BR PI0411316A BR PI0411316 A BRPI0411316 A BR PI0411316A
Authority
BR
Brazil
Prior art keywords
clostridial toxin
reduce appetite
appetite
toxin
reduce
Prior art date
Application number
BRPI0411316-0A
Other languages
English (en)
Inventor
Martin A Voet
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0411316A publication Critical patent/BRPI0411316A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"USO DE UMA TOXINA CLOSTRìDICA PARA REDUZIR O APETITE". A presente invenção refere-se a métodos para reduzir o apetite pela administração oral de uma toxina clostrídica, tal como toxina botulínica.
BRPI0411316-0A 2003-06-11 2004-06-07 uso de uma toxina clostrìdica para reduzir o apetite BRPI0411316A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/459,767 US20040253274A1 (en) 2003-06-11 2003-06-11 Use of a clostridial toxin to reduce appetite
PCT/US2004/017958 WO2005000343A1 (en) 2003-06-11 2004-06-07 Use of a clostridial toxin to reduce appetite

Publications (1)

Publication Number Publication Date
BRPI0411316A true BRPI0411316A (pt) 2006-07-18

Family

ID=33510866

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411316-0A BRPI0411316A (pt) 2003-06-11 2004-06-07 uso de uma toxina clostrìdica para reduzir o apetite

Country Status (7)

Country Link
US (1) US20040253274A1 (pt)
EP (1) EP1633393A1 (pt)
JP (1) JP2007501285A (pt)
AU (1) AU2004251708A1 (pt)
BR (1) BRPI0411316A (pt)
CA (1) CA2529010A1 (pt)
WO (1) WO2005000343A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7794386B2 (en) * 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20090149831A1 (en) * 2007-12-05 2009-06-11 Goldi Kaul Polymeric Microspheres for Treatment of Obesity
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
CN107049479B (zh) 2009-10-27 2020-10-16 努瓦拉公司 具有可冷却的能量发射组件的递送装置
CN106618731B (zh) 2009-11-11 2020-08-07 努瓦拉公司 用于处理组织和控制狭窄的系统、装置和方法
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
GB201906835D0 (en) * 2019-05-15 2019-06-26 Ucb Biopharma Sprl Dry microparticles
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
US20250064906A1 (en) * 2021-11-23 2025-02-27 AEON Biopharma, Inc. Neurotoxin compositions for use in treating digestive disorders
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (pt) * 1962-07-11
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) * 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US6129685A (en) * 1994-02-09 2000-10-10 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
EP1086702B1 (en) * 1994-05-09 2005-04-13 BINDER, William J. Presynaptic neurotoxins for treatment of migraine headache
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
DE19715794C1 (de) * 1997-04-16 1998-12-03 Roehm Gmbh Laminare Arzneiform und Verfahren zu ihrer Herstellung
EP1658858B2 (en) * 1997-07-15 2014-03-26 The Regents of the University of Colorado Use of botulinum toxin for the treatment of recalcitrant voiding dysfunction
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
EP1053014A4 (en) * 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
AU2001259056A1 (en) * 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
WO2002013854A1 (en) * 2000-08-11 2002-02-21 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US7737109B2 (en) * 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
EP1385879A4 (en) * 2001-05-10 2005-02-02 Univ Queensland DIAGNOSIS AND THERAPY OF CANCER OF REPRODUCTIVE ORGANS
US6558400B2 (en) * 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7601740B2 (en) * 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US20060015151A1 (en) * 2003-03-14 2006-01-19 Aldrich William N Method of using endoscopic truncal vagoscopy with gastric bypass, gastric banding and other procedures
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
KR101330775B1 (ko) * 2004-03-03 2013-11-18 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
US7591806B2 (en) * 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060088533A1 (en) * 2004-10-08 2006-04-27 Charalabos Pothoulakis Methods of treating inflammatory bowel disease
EP1846039A2 (en) * 2005-01-10 2007-10-24 Research Development Foundation Targeted chimeric molecules for cancer therapy
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD

Also Published As

Publication number Publication date
AU2004251708A1 (en) 2005-01-06
US20040253274A1 (en) 2004-12-16
WO2005000343A1 (en) 2005-01-06
CA2529010A1 (en) 2005-01-06
JP2007501285A (ja) 2007-01-25
EP1633393A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
IL154888A0 (en) Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
BR0316027A (pt) Formulações de toxina botulina para administração oral
BR0109703A (pt) Derivados de piperazina
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
MXPA06000407A (es) Isomero c cci-779.
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0211972A (pt) Composição oftálmica
ATE370770T1 (de) Hautreinigungsmittel
MXPA06012961A (es) Ficotoxinas y usos de las mismas.
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MX2024001889A (es) Compuestos deuterados.
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
PL380665A1 (pl) Farmaceutyczne kompozycje
BRPI0411820B8 (pt) composição farmacêutica para administração parenteral, e seus usos
UA81664C2 (ru) Производные дифенилмочевины и их применение, как блокаторов хлоридных каналов
TWI349545B (en) Pharmaceutical composition
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos
DE602004022578D1 (de) Antitumorale terpen-verbindungen
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.